Low Molecular Weight Heparin Market Forecast to 2028 - Global Analysis by Enoxaparin, Dalteparin, Tinzaparin, Fraxiparine, Nadroparin - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Low Molecular Weight Heparin Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Enoxaparin, Dalteparin, Tinzaparin, Fraxiparine, Nadroparin, and Others), Packaging (Multi-Vials and Prefilled Syringes), Application , and End User, and Geography" report has been added to ResearchAndMarkets.com's offering.

The low molecular weight heparin market is expected to grow from US$ 3,658.27 million in 2021 to US$ 5,733.96 million by 2028; it is estimated to grow at a CAGR of 6.6% from 2021 to 2028.

Low molecular weight heparin (LMWH) is a class of anticoagulants. They are used to treat venous thromboembolism (deep vein thrombosis and pulmonary embolism) and myocardial infarction, and prevent blood clots. Low molecular weight heparin offers more advantages than heparin as it has better bioavailability, longer half-life, simplified dosing, predictable anticoagulant response, lower HIT risk, and lower osteoporosis risk.

LMWH can be administered subcutaneously once or twice daily without coagulation monitoring, even when the drug is administered in treatment doses. Most patients do not require coagulation monitoring with LMWH. The effects of unfractionated heparin (UFH) or standard heparin vary from patient to patient.

Therefore, it can only be administered to hospitalized patients under supervision. In addition, the LMWH has more predictable pharmacokinetic properties than unfractionated heparin, which allows its administration in fixed doses based on laboratory monitoring, without the need for dose adjustments.

The low molecular weight fractions of heparin have the molecular weight of ~3,500-8,000 Daltons, while unfractionated heparin has a molecular weight of 15,000 Daltons; thus, the former react less with platelets than the latter. Moreover, the LMWH is less likely to induce immune allergic thrombocytopenia, which is a severe side effect of unfractionated heparin (UFH). This condition is often complicated by arterial thrombosis.

In addition, various properties such as better bioavailability, predictable dose-response, and longer plasma half-life than unfractionated heparin make low molecular weight heparin a preferred choice for anticoagulation therapy. Such advantages of the LMWH over unfractionated heparin are boosting its demand, thereby spurring the market growth.

The global low molecular weight heparin market, based on product type, is segmented into enoxaparin, dalteparin, tinzaparin, fraxiparine, nadroparin, and others. The enoxaparin segment held the largest share of the market in 2021. However, the dalteparin segment is anticipated to register the highest CAGR of 7.1% in the market during the forecast period.

The global low molecular weight heparin market, based on packaging, is bifurcated into multi-vials and prefilled syringes. In 2021, the multi-vials segment held a larger share of the market, whereas the prefilled syringes segment is expected to register the highest CAGR during 2021-2028.

The global low molecular weight heparin market, based on application, has been segmented into deep vein thrombosis, acute coronary syndrome (ACS), pulmonary embolism, and others. The deep vein thrombosis segment held the largest share of the market in 2021. However, the acute coronary syndrome (ACS) segment is anticipated to register the highest CAGR in the market during the forecast period.

The global low molecular weight heparin market, based on end user, has been segmented into hospitals, clinics, ambulatory surgical centers, and others. The hospitals segment held the largest share of the market in 2021. However, the ambulatory surgical centers segment is anticipated to register the highest CAGR in the market during the forecast period.

Key Topics Covered:

1. Introduction

2. Key Takeaways

3. Research Methodology

4. Low Molecular Weight Heparin Market - Market Landscape

4.1 Overview

4.2 PEST Analysis

4.3 Experts Opinion

5. Low Molecular Weight Heparin Market- Key Market Dynamics

5.1 Market Drivers

5.2 Market Restraints

5.3 Market Opportunities

5.4 Future Trends

5.5 Impact Analysis

6. Low Molecular Weight Heparin Market- Global Analysis

6.1 Global Low Molecular Weight Heparin Market Revenue Forecast and Analysis

6.2 Global Low Molecular Weight Heparin Market Revenue Forecast and Analysis

6.3 Market Positioning of Key Players

7. Global Low Molecular Weight Heparin Market Revenue and Forecast To 2028- By Product Type

7.1 Overview

7.2 Global Low Molecular Weight Heparin Market, By Product Type, 2021 & 2028 (%)

7.3 Enoxaparin

7.3.1 Overview

7.3.2 Enoxaparin: Low Molecular Weight Heparin Market Revenue and Forecast to 2028 (US$ Million)

7.4 Dalteparin

7.5 Nadroparin

7.6 Fraxiparine

7.7 Tinzaparin

8. Low Molecular Weight Heparin Market Revenue and Forecast To 2028 - Packaging

8.1 Overview

8.2 Global Low Molecular Weight Heparin Market Share by Packaging - 2021 & 2028 (%)

8.3 Multi-Vials

8.3.1 Overview

8.3.2 Multi-Vials: Low Molecular Weight Heparin Market Revenue and Forecast to 2028 (US$ Million)

8.4 Prefilled Syringes

9. Global Low Molecular Weight Heparin Market Revenue and Forecast To 2028- By Application

9.1 Overview

9.2 Global Low Molecular Weight Heparin Market, By Application, 2021 & 2028 (%)

9.3 Deep Vein Thrombosis

9.3.1 Overview

9.3.2 Deep Vein Thrombosis: Low Molecular Weight Heparin Market Revenue and Forecast to 2028 (US$ Million)

9.4 Acute Coronary Syndrome (ACS)

9.5 Pulmonary Embolism

10. Global Low Molecular Weight Heparin Market Revenue and Forecast To 2028- By End User

10.1 Overview

10.2 Global Low Molecular Weight Heparin Market, By End User, 2021 & 2028 (%)

10.3 Hospitals

10.3.1 Overview

10.3.2 Hospitals: Low Molecular Weight Heparin Market Revenue and Forecast to 2028 (US$ Million)

10.4 Clinics

10.5 Ambulatory Surgical Centers

11. Low Molecular Weight Heparin Market Revenue and Forecast to 2028 - Geographical Analysis

12. Impact of COVID-19 Pandemic on Global Low Molecular Weight Heparin Market

13. Low Molecular Weight Heparin Market-Industry Landscape

13.1 Overview

13.2 Growth Strategies in the Low Molecular Weight Heparin Market (%)

13.3 Organic Developments

13.4 Inorganic Developments

14. Company Profiles

• Aspen Holdings
• Changzhou Qianhong Bio-pharma
• LEOPHARMA A/S
• Teva Pharmaceutical Industries Ltd.
• B. Braun Medical Inc.
• Pfizer Inc.
• Sanofi-Aventis
• Dr. Reddy's Laboratories Limited
• Abbott

For more information about this report visit https://www.researchandmarkets.com/r/hzfzvs

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900